Alembic Pharma Expands US Complex Generics with DifGen
Alembic Pharmaceuticals Limited has expanded its strategic collaboration with DifGen Pharmaceuticals to bolster its complex generics portfolio in the US. This partnership leverages DifGen's development and US manufacturing capabilities with Alembic's established US commercial platform. DifGen will manage development, regulatory, manufacturing, and supply, while Alembic will handle manufacturing of select products and US commercialization. The collaboration aims to develop over 20 differentiated products across various complex dosage forms, targeting a reference market of approximately US$5 billion. Initial product launches are anticipated from FY28, with potential for Day 1 launches and products facing limited competition. The agreement also includes reserving capacity at DifGen's US facilities and a framework for building future US manufacturing capabilities for Alembic.
Key Highlights
- Expanded collaboration with DifGen for US complex generics.
- Portfolio of 20+ differentiated products targeting $5 billion market.
- Initial launches expected from FY28 with near-term revenue visibility.
- Enhances US commercial platform and manufacturing capabilities.
- Capital-efficient strategy to deepen US pipeline and growth.
Price Impact
More from APLLTD